Andere Sprachen Biocon Limited

Aktien

A0B91K

INE376G01013

BIOCON

Markt geschlossen - NSE India S.E. Andere Börsenplätze 13:43:47 19.04.2024			% 5 Tage	% 1. Jan.
261.6 ^INR	-2.08%		-4.51%	+4.81%

18.04.	Das indische Unternehmen Biocon entwickelt seine eigene Version von Wegovy, klinische Studie wahrscheinlich nächstes Jahr	RE
17.04.	Biocon Limited unterzeichnet einen exklusiven Lizenz- und Liefervertrag mit Biomm S.A.	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

India's Biocon developing its own version of Wegovy, clinical trial likely next year	18.04.
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	18.04.
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	17.04.
Biocon Board to Consider Dividend for Fiscal 2024	11.04.
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03.04.
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	01.04.
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.	28.03.
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	27.03.
Updates On Aflibercept BPCIA Litigation	26.03.
Biocon Limited Receives an Order from the Reserve Bank of India	22.03.
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15.03.
Biocon's CFO Resigns	15.03.
Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer	14.03.
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14.03.
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14.03.
Biocon Limited Announces Executive Appointments	04.03.
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada	04.03.
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara	01.03.
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	29.02.
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Biocon Limited

Aktien

A0B91K

INE376G01013

BIOCON

Andere Sprachen

Filter